Sphere Fluidics Awarded Gold Accreditation by Investors in People

Internationally-recognized ‘We invest in people’ award is certified recognition of the Company’s care and commitment to its employees globally

Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced that it has received the ‘We invest in people’ Gold accreditation, a prestigious award presented by Investors in People (IIP). This accolade is in recognition of the Company’s commitment to excellence in people management and continuous improvement in workplace practices.

The IIP framework is a globally-recognized standard for people management, defining what it takes to lead, support, and manage people effectively to achieve sustainable results. Presentation of the Gold accreditation signifies how Sphere Fluidics has not only met but surpassed the high standards set by IIP when assessing the Company’s practices, policies, and overall approach to investment in people. The award demonstrates an outstanding commitment to empowering employees, fostering an inclusive culture, and driving performance through effective leadership and management practices.

Sphere Fluidics has always placed a high priority on the well-being and development of its employees, understanding that a motivated and engaged workforce is essential for driving innovation and achieving strategic goals. This prestigious award is a reflection of the Company’s robust HR practices, including comprehensive professional development programs, a strong emphasis on work-life balance, and an inclusive, collaborative workplace environment.

Dale Levitzke, CEO of Sphere Fluidics, expressed his pride in the achievement:

“Receiving the Gold Investors in People Award is a significant milestone for Sphere Fluidics. It recognizes the dedication and hard work of our entire team in creating a workplace where people feel valued, supported, and empowered to reach their full potential. This award is not just a tribute to our HR practices, but a testament to our commitment to nurturing a culture of excellence and continuous improvement.”

Denise Emsden, VP of People & Organizational Development, Sphere Fluidics added: “We are extremely proud to receive this award; a reflection of the dedication to our team and desire to ensure Sphere Fluidics is a great place to work for all our employees. It’s an honor to receive this recognition of our commitment and ambition to deliver important benefits and support to our team.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”